FindTrial
Sign In

SCO-101

DRUG2 trials

Sponsors

Scandion Oncology A/S

Conditions

Inoperable DiseaseLocalized Pancreatic AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaMetastatic Colorectal CancerMetastatic Pancreatic Adenocarcinoma

Phase 1

A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
NCT04247256
Scandion Oncology A/SMetastatic Colorectal Cancer
Start: 2020-05-14End: 2022-06-30Target: 35Updated: 2022-03-02
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
NCT04652206
Scandion Oncology A/SInoperable Disease, Localized Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma +1
Start: 2020-10-27End: 2022-05-15Target: 18Updated: 2021-12-29

Related Papers

PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer.
2025-04-241 citations
Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI.
Journal of Clinical Oncology2022-01-19
Abstract P077: SCO-101 mediates re-sensitization of irinotecan (SN38) resistant colorectal cancer cells
Molecular Cancer Therapeutics2021-12-011 citations
Abstract PS17-43: Sco-101 is a novel oral drug that reverses antiestrogen resistance in breast cancer cells
Cancer Research2021-02-15